Usa India covid-19 testing patient Usa India

Cipla, Hetero gets nod to manufacture, sell Remdesivir drug to fight COVID-19

Reading now: 266
www.livemint.com

COVID-19 patients, the official added.Earlier, this month ANI had reported that the Central Drug Control Standard Organisation (CDCSO) office of DCGI had granted its permission to US based Gilead Sciences for marketing authorization of its anti-viral drug Remdesivir in India for "restricted emergency use" on hospitalized COVID-19 patients in the wake of virus pandemic.On Saturday, ANI reported reported that DCGI granted domestic firm Glenmark Pharmaceuticals the permission to manufacture and market anti- viral drug favipiravir.Gilead had signed non-exclusive voluntary licensing agreements with five generic pharma firms -- Cipla, Jubilant Life Sciences, Hetero, BRD and Mylan to manufacture and distribute remdesivir, a potential antiviral.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA